Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | August 2011 |
| End Date: | June 2014 |
The purpose of this study is to understand if small proteins found on the surface of myeloma
cells (called CXCR4 and CD47) or inside the myeloma cells (Pim kinases, sphingolipids, and
pS6) can predict how patients will respond to chemotherapy-treatment and if a small molecule
inside the myeloma cells (called Pim kinase) can be used as a treatment target for myeloma. A
sample from the bone marrow biopsy (a small amount of tissue removed from the body for
laboratory testing) and aspirate (a small amount of fluid is removed from the body for
laboratory testing) that had been done before the subject entered this study will be provided
for research purposes. Based on preliminary data, it is hypothesized that CXCR4, CD47,
sphingolipids, and Pim kinases could be used as prognostic/predictive markers and that Pim
kinase inhibitors provide a new agent for the treatment of multiple myeloma.
cells (called CXCR4 and CD47) or inside the myeloma cells (Pim kinases, sphingolipids, and
pS6) can predict how patients will respond to chemotherapy-treatment and if a small molecule
inside the myeloma cells (called Pim kinase) can be used as a treatment target for myeloma. A
sample from the bone marrow biopsy (a small amount of tissue removed from the body for
laboratory testing) and aspirate (a small amount of fluid is removed from the body for
laboratory testing) that had been done before the subject entered this study will be provided
for research purposes. Based on preliminary data, it is hypothesized that CXCR4, CD47,
sphingolipids, and Pim kinases could be used as prognostic/predictive markers and that Pim
kinase inhibitors provide a new agent for the treatment of multiple myeloma.
Inclusion Criteria:
- A diagnosis of multiple myeloma or possible multiple myeloma who will have a bone
marrow biopsy and aspirate
- Planned therapy with standard chemotreatment for multiple myeloma
- Laboratory data such as calcium, beta 2-microglobulin, albumin, creatinine and bone
survey available for staging purpose.
- ≥18 years old
Exclusion Criteria:
- < 18 years old
- Patients who will not receive chemotreatment
- Patients whose treatment records are not available
We found this trial at
1
site
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
